Want to see NUTX full AI Analyst Report?
NUTX Stock Chart & Stats
$184.11
-$1.17(-3.51%)
At close: 4:00 PM EST
$184.11
-$1.17(-3.51%)
Day’s Range― - ―
52-Week Range$77.21 - $193.07
Previous CloseN/A
Volume3.28K
Average Volume (3M)121.61K
Market Cap
$1.31B
Enterprise Value$1.01B
Total Cash (Recent Filing)$207.35M
Total Debt (Recent Filing)$349.09M
Price to Earnings (P/E)14.2
Beta2.08
Next Earnings
Aug 06, 2026EPS Estimate
4.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)13.44
Shares Outstanding6,881,339
10 Day Avg. Volume116,976
30 Day Avg. Volume121,608
Financial Highlights & Ratios
PEG Ratio1.68
Price to Book (P/B)3.18
Price to Sales (P/S)1.20
P/FCF Ratio4.26
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue1.15
Enterprise Value/Gross Profit2.43
Enterprise Value/Ebitda3.47
Forecast
1Y Price Target
$233.33Price Target Upside26.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)21.22
Revenue Forecast (FY)$881.34M
Bulls Say, Bears Say
Bulls Say
Strong Free Cash Flow GenerationSustained high operating and free cash flow (TTM ~$270M) indicates durable earnings quality and internal funding capacity. This supports capital returns, debt reduction, and reinvestment into hospital builds and IT without immediate reliance on external financing, improving long‑term financial flexibility and resilience.
Marked Balance-sheet DeleveragingDebt reduction to sub‑1x D/E and higher equity cushions lower financial risk and increases capacity to fund growth projects and withstand reimbursement shocks. Improved ROE (~24% TTM) reflects stronger earnings power on capital, making the balance sheet more durable through industry cycles.
Scalable Growth Strategy: Hospital Builds + Population HealthCombining an internal development pipeline (repeatable $20–30M projects, planned 3–5/year) with an expanding population health platform (~40k patients) creates multiple durable growth levers. Vertical integration and recurring platform revenue can enhance margins long term as scale and care-management capabilities expand.
Bears Say
Significant Gross Margin CompressionA >13pp drop in gross margin reflects rising facility and supply costs and arbitration impacts, signaling pressure on unit economics. If higher operating cost levels persist, margin recovery may be slow, challenging sustainable profitability despite revenue growth and cash flow gains.
Arbitration/IDR Accounting And Timing VolatilityAccounting that front‑loads arbitration costs versus staggered revenue recognition injects recurring earnings volatility and complicates margin visibility. This structural timing mismatch can persist as IDR remains a material revenue channel, making forecasting and stable EBITDA generation more difficult over medium term.
Rising Accounts Receivable And Working-capital SensitivityMaterial AR growth (~$20M quarter) tied to IDR collections increases working capital needs and cash conversion risk. Persistent AR elevation can strain liquidity and operational flexibility, especially if reimbursement timing or recovery rates worsen, making free cash generation less predictable.
Clinigence Holdings News
NUTX FAQ
What was Clinigence Holdings Inc’s price range in the past 12 months?
Clinigence Holdings Inc lowest stock price was $77.21 and its highest was $193.07 in the past 12 months.
What is Clinigence Holdings Inc’s market cap?
Clinigence Holdings Inc’s market cap is $1.31B.
When is Clinigence Holdings Inc’s upcoming earnings report date?
Clinigence Holdings Inc’s upcoming earnings report date is Aug 06, 2026 which is in 35 days.
How were Clinigence Holdings Inc’s earnings last quarter?
Clinigence Holdings Inc released its earnings results on Apr 30, 2026. The company reported $6.52 earnings per share for the quarter, beating the consensus estimate of $3.993 by $2.527.
Is Clinigence Holdings Inc overvalued?
According to Wall Street analysts Clinigence Holdings Inc’s price is currently Undervalued.
Does Clinigence Holdings Inc pay dividends?
Clinigence Holdings Inc does not currently pay dividends.
What is Clinigence Holdings Inc’s EPS estimate?
Clinigence Holdings Inc’s EPS estimate is 4.95.
How many shares outstanding does Clinigence Holdings Inc have?
Clinigence Holdings Inc has 6,881,339 shares outstanding.
What happened to Clinigence Holdings Inc’s price movement after its last earnings report?
Clinigence Holdings Inc reported an EPS of $6.52 in its last earnings report, beating expectations of $3.993. Following the earnings report the stock price went up 17.089%.
Which hedge fund is a major shareholder of Clinigence Holdings Inc?
Currently, no hedge funds are holding shares in NUTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clinigence Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$233.33 (26.74% Upside)
$233.33 (26.74% Upside)
Blogger Sentiment
Neutral
NUTX Sentiment 50%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.27%
12-Months-Change
Fundamentals
Return on Equity
31.39%
Trailing 12-Months
Asset Growth
25.65%
Trailing 12-Months
Company Description
Clinigence Holdings Inc
Nutex Health, Inc. functions as a technology-powered enterprise delivering healthcare services, structured into two key segments: its Hospital division and its Population Health Management division. The Hospital division is tasked with developing and overseeing various healthcare models, encompassing micro-hospitals, specialized medical centers, and hospital outpatient facilities. This segment currently owns and operates 21 locations spanning eight different states. Meanwhile, the Population Health Management division establishes and manages provider networks, such as independent physician associations. Additionally, its management services organizations furnish administrative, operational, and support assistance to its associated hospitals and physician groups. A proprietary, cloud-based technology platform within this division is crucial; it aggregates patient and provider data from multiple information systems, settings, and sources to construct a holistic view, thereby enabling more effective care delivery. The company maintains its corporate headquarters in Houston, Texas.
NUTX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: operationally and strategically Nutex demonstrates strong liquidity, improved net income, positive cash flow, active share repurchases, patient satisfaction, and a clear strategy to internalize development and scale population health. However, significant margin pressure and a 21% drop in adjusted EBITDA driven by higher facility costs and timing effects from IDR/arbitration recognition temper the results. Same-hospital revenue growth was minimal and accounts receivable rose, highlighting near-term execution and working capital considerations. Regulatory and arbitration accounting dynamics introduce additional volatility. Overall, positive cash generation and strategic initiatives are balanced by meaningful margin and accounting headwinds.View all NUTX earnings summariesNUTX Stock 12 Month Forecast
Average Price Target
$233.33
▲(26.74% Upside)
Technical Analysis
HealthStream
―
Evolent Health
―
Health Catalyst
―
10x Genomics
―
Definitive Healthcare Corp
―
Ownership Overview
32.86% Insiders
6.87% Mutual Funds
11.89% Other Institutional Investors
34.94% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---